I know that there were talks between PLX and TEVA few years ago and I thought a bid is on its way, but TEVA was not serious enough. Later they met again and collaborate to develop a compound together. Using the PLX platform to produce biosimilar product has the advantage of not having to wait for the patent to go off and the production amounts are much higher than those you get from CHO cells, so price can be lower . And of course less troubles with the FDA since it is a biosimilar.
Enbrel sounds like a good bet, matches at all points.
How about Avastin and Herceptin, do they fit to the time frame with their off patent dates? They do fit in sales size and being produced in CHO.
Regards, Idit
Market Data 
Markets 
AI
